Treatment
Cell clinical trials
We’re tracking 5,710 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT07479797RecruitingPhase 3
Comparing two CAR T-cell therapies for large B-cell lymphoma after first treatment
This trial tests a new CAR T-cell therapy, KITE-753, against an approved one, Yescarta (axicabtagene ciloleucel), for people with large B-cell lymphoma that came back or didn't respond to first-line treatment. The goal is to see which works better.
Goodyear, ArizonaAges 18 years+ - NCT03391778Enrolling by invitationPhase 1
Long-term follow-up for cell therapy participants
This study checks how people do over time after receiving an “adoptive cell therapy” treatment. It helps researchers understand long-term safety and outcomes after prior participation in related studies.
Atlanta, GeorgiaAges Any age - NCT06596954Recruiting
Lymphocyte-sparing radiation for esophageal cancer
This trial tests a special type of radiation therapy that aims to spare your immune cells (lymphocytes) while treating esophageal cancer. It may help patients with locally advanced esophageal squamous cell carcinoma who are in good overall health.
Shanghai, ChinaAges 18–80 - NCT07659782RecruitingPhase 2
Study of VS-7375 for KRAS G12D lung cancer
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
Los Angeles, CaliforniaAges 18 years+ - NCT07239596RecruitingPhase 1/Phase 2
Study of three drugs for advanced kidney cancer
This trial tests a combination of three drugs (SHR-8068, adebrelimab, and another anti-tumor drug) for people with advanced kidney cancer (clear cell type). The goal is to see if the combination works better than current treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07108387RecruitingPhase 2
Stopping or reducing tocilizumab for well-controlled giant cell arteritis
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
Atlanta, GeorgiaAges 50 years+ - NCT04253964RecruitingPhase 2
Chemotherapy plus immunotherapy for advanced lung cancer
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
Winston-Salem, North CarolinaAges 18 years+ - NCT07541170RecruitingPhase 3
Testing divarasib after lung cancer surgery and chemotherapy
This study tests whether a drug called divarasib can help prevent lung cancer from coming back after surgery and initial treatment. You would only qualify if your cancer has a specific genetic mutation (KRAS G12C) and you've already had surgery and chemotherapy with immunotherapy.
Clovis, CaliforniaAges 18 years+ - NCT07361497RecruitingPhase 3
New Drug vs Standard Drug After Chemoradiation for Stage 3 Lung Cancer
This study tests a new drug, pumitamig, against an older drug, durvalumab, for people with stage 3 non-small cell lung cancer that cannot be removed by surgery and has not progressed after chemotherapy and radiation. The goal is to see which drug works better to keep the cancer from growing.
Daphne, AlabamaAges 18 years+ - NCT07668752RecruitingPhase 3
New pill (GFH375) vs chemo for KRAS G12D lung cancer
This study tests a new pill (GFH375) against a standard chemotherapy (docetaxel) for advanced lung cancer with a specific KRAS G12D mutation. If you have already tried platinum chemo and an immunotherapy, this trial might offer a new option.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07375290RecruitingPhase 1
Zoledronate for Bone Health After Stem Cell Transplant
This trial tests if a bone-strengthening medicine called zoledronate can help prevent bone problems in children and teens who have had a stem cell transplant. It may be an option for patients with low bone density or those who develop graft-versus-host disease after transplant.
Cincinnati, OhioAges 5–18 - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Birmingham, AlabamaAges Up to 30 years - NCT07361510RecruitingPhase 3
Pumitamig vs Keytruda for advanced lung cancer with high PD-L1
This trial compares an experimental drug called Pumitamig with the approved immunotherapy drug Pembrolizumab (Keytruda) as the first treatment for advanced lung cancer that has high PD-L1 levels. The goal is to see which drug works better and has fewer side effects.
Daphne, AlabamaAges 18 years+ - NCT07489495RecruitingPhase 3
Belzutifan and zanzalintinib for advanced kidney cancer
This study tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that has not responded well to other treatments. The goal is to see if the combination slows down cancer growth.
Marietta, GeorgiaAges 18 years+ - NCT07063745RecruitingPhase 2/Phase 3
Comparing a new drug combo for advanced lung cancer with a specific gene change
This trial tests a new drug called Navlimetostat combined with pembrolizumab and chemotherapy versus a placebo with the same standard treatments. It is for people with metastatic non-small cell lung cancer that has a specific missing gene (MTAP deletion) and who have not had prior treatment for their advanced disease.
Anchorage, AlaskaAges 18 years+ - NCT07739654RecruitingPhase 3
Modified chemotherapy combo for relapsed large b-cell lymphoma
This study compares two chemotherapy regimens for people with diffuse large B-cell lymphoma that has returned or not responded to earlier treatment. The goal is to see if a modified version is as effective with fewer side effects.
Lahore, Punjab ProvinceAges 18 years+ - NCT06567704Recruiting
Fatigue from immunotherapy in lung cancer: a patient interview study
This study aims to understand how maintenance immunotherapy affects fatigue in people with non-small cell lung cancer. Researchers will talk with patients to learn about their experiences.
Charlotte, North CarolinaAges 18 years+ - NCT07513376RecruitingPhase 3
Adjuvant vaccine plus immunotherapy for high-risk early lung cancer
This trial tests whether giving a personalized cancer vaccine (Intismeran) with or without an immunotherapy drug (pembrolizumab) after lung cancer surgery can help prevent the cancer from coming back in patients with early-stage, high-risk non-small cell lung cancer.
New Haven, ConnecticutAges 18 years+ - NCT06623422RecruitingPhase 3
Vaccine plus Keytruda for lung cancer after surgery
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
Gilbert, ArizonaAges 18 years+ - NCT06798298Recruiting
Long-term safety study of gene modified T cell treatment
This study is a long-term safety check for people who have already received a gene modified T cell treatment in a previous study sponsored by 2seventy bio or Regeneron Pharmaceuticals. The goal is to monitor your health for years after that treatment to see how well it works and if any side effects appear over time.
Nashville, TennesseeAges 18 years+ - NCT06784336RecruitingPhase 2
Testing starch and a drug after stem cell transplant
This trial tests if adding a special starch and a drug called deferasirox can improve recovery for people who have a stem cell transplant for blood disorders. The starch may help with gut health and the drug reduces iron, which might help prevent complications.
Ann Arbor, MichiganAges 18 years+ - NCT06514898RecruitingPhase 1
Personalized cell therapy for recurrent medulloblastoma
This trial tests a combination of personalized immune cells, vaccines, stem cells, and an immunotherapy drug (pembrolizumab) for children and young adults whose medulloblastoma has come back or grown. The goal is to help the immune system fight the cancer more effectively.
Washington D.C., District of ColumbiaAges 4–30 - NCT07752953Recruiting
Personalized immune cell therapy for solid tumors
This trial tests a personalized cancer vaccine made from your own immune cells to help your body fight the tumor. It is for people with solid tumors that have not responded to other treatments.
Qinhuangdao, HebeiAges 18–75 - NCT07751380RecruitingPhase 1
CAR T-cell therapy for children and young adults with certain sarcomas
This trial tests a new kind of cell therapy called CAR T-cells that are engineered to find and attack sarcoma cells carrying a marker called B7-H3. It is for children and young adults whose sarcoma has come back or not gone away after treatment.
LondonAges 1–24
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,710 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.